leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 14:20:33 - browse：5

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： What Henrietta Lacks settlement says about racism in medicine

WSS

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Weight loss drug costs may need more research, senator suggests

Morphosys mixed study results for blood cancer drug

Surge of respiratory disease in China has likely explanation

What Henrietta Lacks settlement says about racism in medicine

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

hotspot

leisure time

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

My superpower is killing ticks

Apple is now the first public company to be valued at $3 trillion

FDA's Woodcock to retire early next year

Heart attack and stroke risk calculators need revising

What the cancer research community can learn from the Covid response

Medicare proposal to cover medical devices draws a mixed reaction

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Continuity nursing helped my family in our darkest PICU moments

TytoCare raises $49 million to build out AI

focus

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Influencer to be charged after chaos erupts in New York City's Union Square

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Influencer to be charged after chaos erupts in New York City's Union Square

TytoCare raises $49 million to build out AI

Morphosys mixed study results for blood cancer drug

knowledge

entertainment

entertainment

leisure time